Suspective gene mutations and family history: To observe if the patients with suspective gene mutations or family history take higher risk of suffering from ovarian cancer.
Study summary
The aim of this project is to establish a bidirectional multicenter cohort of hereditary ovarian cancer and to describe the clinicopathologic features of hereditary ovarian cancer patients in our country. The risk prediction model of ovarian cancer for Chinese was established by following-up analysis of clinical and pathological information, genetic test results and detailed family history, to predict the risk of cancer in first-degree relatives of carriers of pathogenic/suspected pathogenic mutations, and to guide the intervention management of high-risk population of cancer.
The study will identify novel tumor-causing mutations/predisposing genes by gene sequencing in a special family with hereditary tumor.
Eligibility
Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Epithelial ovarian cancer
* ≥18 years
* The pathological diagnosis was clear
* The genetic test showed germ line pathogenic/suspected pathogenic mutations (for mutation interpretation, refer to the American ACMG Classification Standards and Guidelines for Genetic Variation)
Exclusion Criteria:
* Non-epithelial ovarian cancer was confirmed by pathology
* No genetic test has been performed
Primary outcome measure(s)
The clinicopathological features and gene mutation characteristics of hereditary ovarian cancer — 2024-2026 * personal history (age, BMI, oral contraceptive use, hormone replacement therapy use, tubal ligation)
* menstrual marriage and childbearing history (whether or not menopause, menopausal age, menarche age, the number of births)
* personal history of tumor (history of malignant tumor, tumor type, pathological type, tumor stage, age of onset) ④family history of cancer (family history of cancer or not, number/person of cancer in first/second/third degree relatives, relationship with patients, tumor type, pathological type, tumor stage, age of onset, gene detection) ⑤results of gene detection (detection items, specimen type, mutation, mutated gene, cDNA change, amino acid change, mutation type, mutation significance)
Trial sites (1)
Facility
City
Region
Status
Peking University Third Hospital
Beijing
Beijing Municipality
Recruiting
More Peking University Third Hospital trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.